Overview

Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma

Status:
Completed

Trial end date:
2007-06-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of GSK256066 in the treatment of subjects with mild bronchial asthma, using a number of clinical and biological markers of efficacy.

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

6-((3-((dimethylamino)carbonyl)phenyl)sulfonyl)-8-methyl-4-((3-methyloxyphenyl)amino)-3-quinolinecarboxamide